Jupiter Neurosciences (JUNS) Common Equity (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Common Equity of -$1.8 million for Q4 2025, down 143.91% year-over-year from $4.2 million in Q4 2024, and down 3290.43% quarter-over-quarter from $57417.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Common Equity (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Common Equity for 3 consecutive years, with -$1.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 143.91% year-over-year to -$1.8 million; the TTM figure through Dec 2025 stood at -$1.8 million (down 143.91% YoY), while the FY2025 annual figure was -$1.8 million, down 143.91% from the prior year.
- Common Equity eased to -$1.8 million in Q4 2025 per JUNS's latest filing, from $57417.0 in the prior quarter.
- Across five years, Common Equity topped out at $4.2 million in Q4 2024 and bottomed at -$6.3 million in Q3 2023.
- Historically, Common Equity has averaged -$2.2 million across 3 years, with a median of -$3.6 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity surged 171.91% — and 2025, when it tumbled 143.91%.
- Jupiter Neurosciences' Common Equity stood at -$5.8 million in 2023, then jumped by 171.91% to $4.2 million in 2024, then sank by 143.91% to -$1.8 million in 2025.
- Business Quant data shows JUNS's Common Equity at -$1.8 million in Q4 2025, $57417.0 in Q3 2025, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | -365,966.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.83 Mn |
| Sep 30, 2025 | 57,417.00 |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 4.17 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Jun 30, 2024 | -5.36 Mn |
| Mar 31, 2024 | -6.02 Mn |
| Dec 31, 2023 | -5.80 Mn |
| Sep 30, 2023 | -6.27 Mn |